These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 4726231

  • 1. Spironolactone as a nonspecific treatment for primary aldosteronism.
    Bravo EL, Dustan HP, Tarazi RC.
    Circulation; 1973 Sep; 48(3):491-8. PubMed ID: 4726231
    [No Abstract] [Full Text] [Related]

  • 2. Plasma renin activity in the diagnosis of primary aldosteronism: failure to distinguish primary aldosteronism from essential hypertension.
    Jose A, Kaplan NM.
    Arch Intern Med; 1969 Feb; 123(2):141-6. PubMed ID: 5812600
    [No Abstract] [Full Text] [Related]

  • 3. Studies on essential hypertension with suppressed plasma renin activity: sodium excretion pattern on salt restriction and effects of spironolactone on blood pressure and plasma renin activity.
    Uchida K, Morimoto S, Takeda R, Murakami M.
    Jpn Circ J; 1972 Dec; 36(12):1301-11. PubMed ID: 4679217
    [No Abstract] [Full Text] [Related]

  • 4. The syndrome of primary aldosteronism.
    George JM, Wright L, Bell NH, Bartter FC.
    Am J Med; 1970 Mar; 48(3):343-56. PubMed ID: 5435648
    [No Abstract] [Full Text] [Related]

  • 5. Treatment of low-renin essential hypertension. Comparison of spironolactone and a hydrochlorothiazide-triamterene combination.
    Douglas JG, Hollifield JW, Liddle GW.
    JAMA; 1974 Feb 04; 227(5):518-21. PubMed ID: 4589187
    [No Abstract] [Full Text] [Related]

  • 6. Effect of spironolactone on fluid volumes and adrenal steroids in primary aldosteronism.
    Ichikawa S, Tajima Y, Sakamaki T, Matsuo H, Kogure M, Hirano Y, Yagi S, Murata K.
    Jpn Circ J; 1984 Nov 04; 48(11):1184-96. PubMed ID: 6502914
    [Abstract] [Full Text] [Related]

  • 7. Does prolonged pretreatment with large doses of spironolactone hasten a recovery from juxtaglomerular-adrenal suppression in primary aldosteronism?
    Morimoto S, Takeda R, Murakami M.
    J Clin Endocrinol Metab; 1970 Dec 04; 31(6):659-64. PubMed ID: 4921649
    [No Abstract] [Full Text] [Related]

  • 8. The occurrence of hyperaldosteronism in infants with congestive heart failure.
    Baylen BG, Johnson G, Tsang R, Srivastava L, Kaplan S.
    Am J Cardiol; 1980 Feb 04; 45(2):305-10. PubMed ID: 6986745
    [Abstract] [Full Text] [Related]

  • 9. Volume-dependent essential and steroid hypertension.
    Dustan HP, Bravo EL, Tarazi RC.
    Am J Cardiol; 1973 May 04; 31(5):606-15. PubMed ID: 4698131
    [No Abstract] [Full Text] [Related]

  • 10. Volume factor in low and normal renin essential hypertension. Treatment with either spironolactone or chlorthalidone.
    Vaughan ED, Laragh JH, Gavras I, Bühler FR, Gavras H, Brunner HR, Baer L.
    Am J Cardiol; 1973 Sep 20; 32(4):523-32. PubMed ID: 4729722
    [No Abstract] [Full Text] [Related]

  • 11. Renin-angiotensin-aldosterone system of a woman with Bartter's syndrome: Juxtaglomerular cell hyperplasia without hypertension.
    Nakada T, Momose G, Yoshida T, Tateno Y, Shigematsu H.
    J Urol; 1974 Sep 20; 112(3):293-8. PubMed ID: 4369140
    [No Abstract] [Full Text] [Related]

  • 12. High doses of spironolactone (Aldactone, SC-14266, Verospirone) alone and in combination with triamterene and-or diuretics in the treatment of refractory edema associated with secondary hyperaldosteronism.
    Radó JP, Marosi J, Takó J.
    Endokrinologie; 1970 Sep 20; 57(1):46-62. PubMed ID: 4923990
    [No Abstract] [Full Text] [Related]

  • 13. Studies of the renin-angiotensin-aldosterone system in patients with hypertension and in normal subjects.
    Streeten DH, Schletter FE, Clift GV, Stevenson CT, Dalakos TG.
    Am J Med; 1969 Jun 20; 46(6):844-61. PubMed ID: 4307877
    [No Abstract] [Full Text] [Related]

  • 14. Comparison of surgery and prolonged spironolactone therapy in patients with hypertension, aldosterone excess, and low plasma renin.
    Brown JJ, Davies DL, Ferriss JB, Fraser R, Haywood E, Lever AF, Robertson JI.
    Br Med J; 1972 Jun 24; 2(5816):729-34. PubMed ID: 4338668
    [Abstract] [Full Text] [Related]

  • 15. Hyporeninemic hypertension.
    Crane MG, Harris JJ, Johns VJ.
    Am J Med; 1972 Apr 24; 52(4):457-66. PubMed ID: 5017240
    [No Abstract] [Full Text] [Related]

  • 16. [Spironolactone and thiabutazide in the treatment of essential hypertension (author's transl)].
    Klump F, Braun B, Klaus D, Lemke R, Zehner J, Zöfel P.
    Dtsch Med Wochenschr; 1975 Mar 21; 100(12):577-84. PubMed ID: 1168122
    [Abstract] [Full Text] [Related]

  • 17. Aldosterone response to adrenocorticotrophin and furosemide in primary aldosteronism after prolonged spironolactone treatment.
    Yagi A, Ichikawa S, Sakamaki T, Ono Z, Sato K, Nakamura T, Sakamoto H, Murata K.
    Eur J Endocrinol; 1994 Sep 21; 131(3):215-20. PubMed ID: 7921203
    [Abstract] [Full Text] [Related]

  • 18. Bilateral adrenal hyperplasia as a cause of primary aldosteronism with hypertension, hypokalemia and suppressed renin activity.
    Davis WW, Newsome HH, Wright LD, Hammond WG, Easton J, Bartter FC.
    Am J Med; 1967 Apr 21; 42(4):642-7. PubMed ID: 6024721
    [No Abstract] [Full Text] [Related]

  • 19. Influence of aldosterone on sodium, water and potassium metabolism in chronic renal disease.
    Schrier RW, Regal EM.
    Kidney Int; 1972 Mar 21; 1(3):156-68. PubMed ID: 4671219
    [No Abstract] [Full Text] [Related]

  • 20. Spironolactone and amiloride in the treatment of low renin hyperaldosteronism and related syndromes.
    Kremer D, Beevers DG, Brown JJ, Davies DL, Ferriss JB, Fraser R, Lever AF, Robertson JI.
    Clin Sci Mol Med Suppl; 1973 Aug 21; 45 Suppl 1():213s-8. PubMed ID: 4361398
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.